Today it was reported that a Director at Spark Therapeutics (ONCE), Anand Mehra, exercised options to buy 37,203 ONCE shares at $3.45 a share, for a total transaction value of $128.4K.
Following this transaction Anand Mehra’s holding in the company was increased by 7.71% to a total of $22.9 million. This is Mehra’s first Buy trade following 5 Sell transactions.
See today’s analyst top recommended stocks >>
Based on Spark Therapeutics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $10.71 million and GAAP net loss of $47.36 million. In comparison, last year the company earned revenue of $7.41 million and had a GAAP net loss of $61.82 million. Currently, Spark Therapeutics has an average volume of 724.1K.
Based on 13 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $62.18, reflecting a 39.6% upside. Eight different firms, including Cantor Fitzgerald and Cowen & Co., currently also have a Buy rating on the stock.
The insider sentiment on Spark Therapeutics has been positive according to 20 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases.
